C6orf136 Inhibitors
Chemical inhibitors of C6orf136 act through various intracellular signaling pathways to inhibit its function. Wortmannin and LY294002 are two compounds that exert their inhibitory effects by targeting the PI3K/Akt pathway. Wortmannin is a potent inhibitor of PI3K, which is upstream of the Akt kinase that plays a pivotal role in C6orf136-related signaling processes. The inhibition by Wortmannin leads to a reduction in Akt phosphorylation, thereby impeding the downstream signaling essential for C6orf136 functionality. Similarly, LY294002 directly inhibits PI3K, resulting in diminished Akt activity and subsequently decreased activity of C6orf136 due to suppression of the necessary signaling pathways.
Rapamycin and Torin 1 work further downstream by inhibiting mTOR, a kinase that is a crucial component of the signaling pathway involving C6orf136. The inhibition of mTOR by these compounds disrupts the signaling required for the activity of C6orf136. PD98059 and U0126 are inhibitors that target the MAPK/ERK pathway. PD98059 inhibits MEK, preventing the activation of ERK, a kinase that contributes to the signaling cascade C6orf136 is involved in. In a similar fashion, U0126 inhibits both MEK1 and MEK2, leading to a disruption in ERK phosphorylation and, consequently, C6orf136 signaling. SP600125 and SB203580 inhibit JNK and p38 MAP kinase, respectively, both of which are implicated in pathways essential for C6orf136 function. Inhibition of these kinases by SP600125 and SB203580 leads to a decrease in C6orf136 activity due to the diminished signaling. PP2, Gefitinib, Lapatinib, and Erlotinib are inhibitors that affect the signaling pathways involving receptor tyrosine kinases. PP2 inhibits Src family kinases, which are upstream of several signaling pathways in which C6orf136 is implicated. The inhibition by PP2 results in reduced C6orf136 activity due to the disruption of necessary downstream signals. Gefitinib, Lapatinib, and Erlotinib inhibit tyrosine kinases such as EGFR and HER2/neu. By preventing the activation of these receptors, these inhibitors lead to a disruption in the downstream signaling cascades that facilitate C6orf136 function, thereby inhibiting the activity of C6orf136. Each of these inhibitors, through their respective targets, ensures a comprehensive attenuation of the signaling pathways necessary for C6orf136 function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. C6orf136 is known to be involved in PI3K-related signaling pathways. By inhibiting PI3K, Wortmannin can reduce AKT phosphorylation, thereby inhibiting downstream signaling processes that are crucial for C6orf136 function, leading to a functional inhibition of C6orf136. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 directly inhibits PI3K, which is upstream of C6orf136's functional pathway. This inhibition results in decreased AKT activity, a kinase that would otherwise contribute to C6orf136 signaling and function. As a result, C6orf136's activity is reduced due to the suppression of necessary PI3K/AKT pathway signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, an important kinase downstream of PI3K/AKT signaling, which C6orf136 is involved in. By inhibiting mTOR, Rapamycin can disrupt the downstream signaling that contributes to C6orf136 activity, leading to functional inhibition of C6orf136. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is another mTOR inhibitor that can disrupt the mTOR signaling pathway. Since C6orf136 is associated with this pathway, Torin 1's inhibition of mTOR leads to reduced signaling necessary for C6orf136 function, resulting in its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. C6orf136 has been implicated in pathways involving MAPK/ERK signaling. By inhibiting MEK, PD98059 can prevent the activation of ERK, thus inhibiting the signaling necessary for C6orf136 activity, leading to functional inhibition of C6orf136. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in signaling pathways associated with C6orf136. The inhibition of JNK leads to a decrease in downstream signaling required for C6orf136's activity, resulting in the functional inhibition of C6orf136. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which plays a role in the pathways that C6orf136 is involved in. By inhibiting p38 MAP kinase activity, SB203580 can prevent the signaling required for C6orf136's function, leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key kinases in the MAPK/ERK pathway where C6orf136 is involved. By inhibiting MEK1/2, U0126 can prevent the necessary phosphorylation of ERK, thereby disrupting the signaling cascade vital for C6orf136 activity, resulting in functional inhibition of C6orf136. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which are implicated in the signaling pathways that involve C6orf136. Inhibition of Src kinase activity by PP2 would disrupt downstream signaling processes essential for C6orf136 function, leading to its functional inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. Given that C6orf136 is involved in EGFR signaling pathways, the inhibition of EGFR by Gefitinib can result in a disruption of downstream signaling necessary for C6orf136's activity, leading to functional inhibition of C6orf136. | ||||||